| Literature DB >> 36112298 |
Rungsima Wanitphakdeedecha1, Tatre Jantarakolica2, Tatchalerm Sudhipongpracha3, Supisara Wongdama4, Mia Katrina R Gervasio4, Ma Christina B Gulfan4, Yuri Yogya4, Krisinda Clare C Dim-Jamora5.
Abstract
INTRODUCTION: The Coronavirus disease 2019 (COVID-19) pandemic has greatly affected medical practices worldwide. Due to the transmissibility of the SARS-CoV-2 virus, the risks and benefits of conducting non-emergent and aesthetic procedures have shifted. This study primarily aimed to investigate the different factors affecting the physician's decision to conduct dermatologic surgery procedures during the COVID-19 pandemic based on their own vaccination status. Secondly, this study also aimed to determine the level of institutional trust in the respondents' respective governments and ministries of health.Entities:
Keywords: COVID-19; Decisions; Dermatologic surgery; Procedures; Vaccines
Year: 2022 PMID: 36112298 PMCID: PMC9483386 DOI: 10.1007/s13555-022-00803-0
Source DB: PubMed Journal: Dermatol Ther (Heidelb)
Respondents categorized by country, specialty, years of experience, and age.
Source: Survey results
| (Observing period) | Thailand | Indonesia | Philippines | Others | Total |
|---|---|---|---|---|---|
| (13/10/21–17/10/21) | (13/10/21–23/11/21) | (13/10/21–29/11/21) | (13/10/21–2/12/21) | (13/10/21–2/12/21) | |
| 80 | 11 | 4 | 13 | 108 | |
| % | 69.6% | 11.6% | 4.4% | 26.0% | 30.8% |
| Years of experience (mean) | 7.7 | 7.4 | 7.3 | 11.2 | 8.1 |
| s.d. | 5.5 | 6.5 | 6.7 | 8.4 | 6.1 |
| Age (mean) | 34.4 | 31.2 | 34.8 | 40.8 | 34.8 |
| s.d. | 6.9 | 12.3 | 9.4 | 7.6 | 8.0 |
| 19 | 79 | 74 | 24 | 196 | |
| % | 16.5% | 83.2% | 81.3% | 48.0% | 55.8% |
| Years of Experience (mean) | 12.1 | 8.7 | 10.3 | 12.8 | 10.1 |
| s.d. | 8.6 | 6.5 | 9.4 | 10.5 | 8.5 |
| Age (mean) | 40.5 | 41.3 | 40.6 | 41.8 | 41.0 |
| s.d. | 9.9 | 7.4 | 11.3 | 11.6 | 9.8 |
| 8 | 5 | 7 | 4 | 24 | |
| % | 7.0% | 5.3% | 7.7% | 8.0% | 6.8% |
| Years of experience (mean) | 6.6 | 8.2 | 10.3 | 17.8 | 9.9 |
| s.d. | 5.4 | 5.7 | 10.5 | 4.8 | 7.8 |
| Age (mean) | 35.6 | 38.4 | 41.0 | 48.5 | 39.9 |
| s.d. | 6.0 | 4.4 | 11.0 | 6.4 | 8.4 |
| 8 | 0 | 6 | 9 | 23 | |
| % | 7.0% | 0.0% | 6.6% | 18.0% | 6.6% |
| Years of experience (mean) | 11.1 | - | 5.0 | 16.0 | 11.4 |
| s.d. | 7.8 | - | 0.6 | 10.0 | 8.7 |
| Age (mean) | 39.1 | - | 31.3 | 45.9 | 39.7 |
| s.d. | 7.8 | - | 0.8 | 9.8 | 9.4 |
| Total | 115 | 95 | 91 | 50 | 351 |
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
Fig. 1Number of vaccine doses received by respondents categorized by country
Estimated results of random effects logit models and subsample analysis based on country
| Variable | Total | Thailand | Indonesia | Philippines | Othersa |
|---|---|---|---|---|---|
| Inactive | 12.46*** | 9.35 *** | 17.49 *** | 37.83 *** | 3.82 *** |
| Viral vector | 29.44*** | 29.64*** | 28.49*** | 60.12*** | 16.16*** |
| mRNA | 36.71*** | 51.62*** | 27.68*** | 62.16*** | 21.86*** |
| Protein-based | 28.57*** | 34.09*** | 22.64*** | 49.25*** | 19.72*** |
| Cancer removal | 1.04 | 0.97 | 0.79 | 1.46** | 1.20 |
| Patient | |||||
| Swab | 77.32*** | 57.31*** | 127.53*** | 188.15*** | 23.18*** |
| Constant | 0.03*** | 0.05*** | 0.01*** | 0.01*** | 0.11*** |
| lnsig2u | 3.81*** | 3.48*** | 3.29*** | 4.62*** | 3.68*** |
| Observations | 7020 | 2300 | 1900 | 1820 | 1000 |
| Respondents | 351 | 115 | 95 | 91 | 50 |
| log-likelihood | − 2563.5 | − 835.6 | − 670.6 | − 596.5 | − 398.1 |
| Chi-square testb | 1507.1*** | 455.1*** | 463.1*** | 369.4*** | 187.6*** |
| LR test (rho = 0)c | 1315.5*** | 389.7*** | 298.4*** | 364.8*** | 199.5*** |
| AUCd | 0.8393 | 0.8367 | 0.8653 | 0.8573 | 0.7951 |
*Significant at 0.1, **significant at 0.05, ***significant at 0.01. Odds ratio is reported
aOther countries consist of Taiwan, 26 obs. (7.41%), Singapore, 7 obs. (1.99%), Cambodia, 7 obs. (1.99%), Malaysia, 6 obs. (1.71%), Hong Kong, 3 obs. (0.85%), and South Korea, 1 obs. (0.28%)
bOverall Chi-square tests of all models indicate that all independent variables in the model can significantly explain decision to treat the patients
cLR tests of all models indicate that respondents’ specific characteristics are significant differences and have been controlled for in the models
dArea under the receiver operating characteristic (ROC) curve (AUC) of all models, which are between 0.7951 to 0.8653, indicate that the estimated models give approximately 80% accurate prediction
Estimated results of random effects logit models and subsample analysis based on specialty
| Variable | Total | General | Derm | D_Surg | Othera |
|---|---|---|---|---|---|
| Inactive | 12.46*** | 11.15*** | 16.80*** | 7.69*** | 5.97*** |
| Viral vector | 29.44*** | 33.30*** | 35.44*** | 18.28*** | 15.47*** |
| mRNA | 36.71*** | 52.72*** | 38.94*** | 31.08*** | 17.43*** |
| Protein-based | 28.57*** | 37.97*** | 30.18*** | 20.80*** | 19.71*** |
| Cancer removal | 1.04 | 0.51*** | 1.37*** | 1.29 | 2.35*** |
| Swab | 77.32*** | 45.99*** | 110.18*** | 263.79*** | 34.43*** |
| Constant | 0.03*** | 0.08*** | 0.01*** | 0.05*** | 0.09*** |
| lnsig2u | 3.81*** | 4.33*** | 3.18*** | 5.18*** | 2.81** |
| Observations | 7020 | 2160 | 3920 | 480 | 460 |
| Respondents | 351 | 108 | 196 | 24 | 23 |
| log-likelihood | − 2563.5 | − 770.2 | − 1409.2 | − 151.8 | − 169.5 |
| Chi-square testb | 1507.1*** | 414.7*** | 906.2*** | 81.6*** | 85.2*** |
| LR test (rho = 0)c | 1315.5*** | 435.2*** | 604.2*** | 100.7*** | 69.6*** |
| AUCd | 0.8393 | 0.8273 | 0.8623 | 0.8568 | 0.8222 |
*Significant at 0.1, ** significant at 0.05, *** significant at 0.01. Odds ratio is reported
aOther countries consist of Taiwan, 26 obs. (7.41%), Singapore, 7 obs. (1.99%), Cambodia, 7 obs. (1.99%), Malaysia, 6 obs. (1.71%), Hong Kong, 3 obs. (0.85%), and South Korea, 1 obs. (0.28%)
bOverall Chi-square tests of all models indicate that all independent variables in the model can significantly explain decision to treat the patients
cLR tests of all models indicate that respondents’ specific characteristics are significant differences and have been controlled for in the models
dArea under the receiver operating characteristic (ROC) curve (AUC) of all models, which are between 0.8222 to 0.8623, indicate that the estimated models give approximately 80% accurate prediction
Estimated results of random effects logit models and subsample analysis based on age
| Variable | Total | Younger than 30 | 30–50 | Older than 50 |
|---|---|---|---|---|
| Inactive | 12.46*** | 10.89*** | 12.62*** | 17.57*** |
| Viral vector | 29.44*** | 35.86*** | 25.05*** | 74.67*** |
| mRNA | 36.71*** | 63.26*** | 29.98*** | 63.53*** |
| Protein-based | 28.57*** | 46.30*** | 23.18*** | 54.05*** |
| Cancer removal | 1.04 | 0.99 | 1.00 | 1.65** |
| Swab | 77.32*** | 31.93*** | 89.38*** | 267.78*** |
| Constant | 0.03*** | 0.05*** | 0.03*** | 0.01*** |
| lnsig2u | 3.81*** | 2.49*** | 3.86*** | 7.51*** |
| Observations | 7020 | 1360 | 4840 | 820 |
| Respondents | 351 | 68 | 242 | 41 |
| log-likelihood | − 2563.5 | − 520.6 | − 1747.9 | − 259.3 |
| Chi-square testa | 1507.1*** | 268.9*** | 1067.8*** | 162.6*** |
| LR test (rho = 0)b | 1315.5*** | 174.8*** | 910.8*** | 232.4*** |
| AUCc | 0.8393 | 0.8351 | 0.8424 | 0.8529 |
*Significant at 0.1, **significant at 0.05, ***significant at 0.01. Odds ratio is reported
aOverall Chi-square tests of all models indicate that all independent variables in the model can significantly explain decision to treat the patients
bLR tests of all models indicate that respondents’ specific characteristics are significant differences and have been controlled for in the models
cArea under the receiver operating characteristic (ROC) curve (AUC) of all models, which are between 0.8351 to 0.8529, indicate that the estimated models give approximately 80% accurate prediction
Fig. 2Physicians’ level of trust in the national government categorized by country
Estimated results of random effects logit models and subsample analysis based on level of trust in the national government
| Variable | Total | LTrust | MTrust | HTrust |
|---|---|---|---|---|
| Vaccine | ||||
| Inactive | 12.46*** | 13.46*** | 12.12*** | 11.65*** |
| Viral vector | 29.44*** | 40.89*** | 19.23*** | 25.26*** |
| mRNA | 36.71*** | 57.62*** | 25.30*** | 26.85*** |
| Protein-based | 28.57*** | 40.18*** | 17.79*** | 24.76*** |
| Procedure | ||||
| Cancer removal | 1.04 | 0.95 | 1.29 | 1.05 |
| Swab | 77.32*** | 77.63*** | 78.03*** | 79.63*** |
| Constant | 0.03*** | 0.03 | 0.03 | 0.02 |
| lnsig2u | 3.81*** | 3.69*** | 3.69*** | 3.84*** |
| Observations | 7020 | 3140 | 1320 | 2560 |
| Respondents | 351 | 157 | 66 | 128 |
| log-likelihood | − 2563.5 | − 1110.0 | − 491.5 | − 948.5 |
| Chi-square testa | 1507.1*** | 627.1*** | 303.1*** | 579.0*** |
| LR test (rho = 0)b | 1315.5*** | 544.5*** | 235.3*** | 502.2*** |
| AUCc | 0.8393 | 0.8433 | 0.8432 | 0.8380 |
*Significant at 0.1, **significant at 0.05, ***significant at 0.01. Odds ratio is reported
LTrust is low level of trust (level not at all and 2). MTrust is moderate level of trust (level 3). HTrust is high level of trust (levels 4 and 5)
aOverall Chi-square tests of all models indicate that all independent variables in the model can significantly explain decision to treat the patients
bLR tests of all models indicate that respondents’ specific characteristics are significant differences and have been controlled for in the models
cArea under the receiver operating characteristic (ROC) curve (AUC) of all models, which are between 0.8380 to 0.8433, indicate that the estimated models give approximately 80% accurate prediction
Fig. 3Physicians’ level of opinion on role of the health ministry categorized by country
Estimated results of random effects logit models and subsample analysis based on level of opinion on role of the health ministry
| Variable | Total | PMoH | MMoH | GMoH |
|---|---|---|---|---|
| Inactive | 12.46*** | 9.42*** | 15.26*** | 14.27*** |
| Viral vector | 29.44*** | 33.50*** | 23.45*** | 32.03*** |
| mRNA | 36.71*** | 48.59*** | 26.88*** | 37.56*** |
| Protein-based | 28.57*** | 35.87*** | 18.39*** | 33.33*** |
| Cancer removal | 1.04 | 1.03 | 1.04 | 1.06 |
| Swab | 77.32*** | 60.86*** | 87.45*** | 91.76*** |
| Constant | 0.03*** | 0.04*** | 0.03*** | 0.02*** |
| lnsig2u | 3.81*** | 3.36*** | 3.96*** | 4.18*** |
| Observations | 7020 | 2300 | 1960 | 2760 |
| Respondents | 351 | 115 | 98 | 138 |
| log-likelihood | − 2563.5 | − 847.8 | − 714.1 | − 986.9 |
| Chi-square testa | 1507.1*** | 473.7*** | 439.6*** | 593.1*** |
| LR test (rho = 0)b | 1315.5*** | 381.7*** | 375.9*** | 558.0*** |
| AUCc | 0.8393 | 0.8398 | 0.8400 | 0.8401 |
*Significant at 0.1, **significant at 0.05, ***significant at 0.01. Odds ratio is reported
PMoH is poor performance of the role of health ministry in dealing with COVID-19 (level very bad and bad). MMoH is moderate performance of the role of MoH in dealing with COVID-19 (level neutral). GMoH is good performance of the role of MoH in dealing with COVID-19 (level good and very good)
aOverall Chi-square tests of all models indicate that all independent variables in the model can significantly explain decision to treat the patients
bLR tests of all models indicate that respondents’ specific characteristics are significantly differences and have been controlled for in the models
cArea under the receiver operating characteristic (ROC) curve (AUC) of all models, which are between 0.8393 to 0.8401, indicate that the estimated models give approximately 80% accurate prediction
| The COVID-19 pandemic has greatly affected medical practices worldwide. |
| The factors that influence the decision to conduct dermatologic surgery procedures during the COVID-19 pandemic include the type of vaccination the doctors received prior to the procedures and the willingness of the patients to undergo pre-procedure nasal swabbing. |
| The type of procedure performed (aesthetic or non-aesthetic type) was a non-significant factor. |